BRAF inhibitors are a class of targeted cancer therapies designed to inhibit the activity of the BRAF protein, which is encoded by the BRAF gene. This protein is a part of the MAPK/ERK signaling pathway, which plays a critical role in cell division and differentiation. Mutations in the BRAF gene, particularly the V600E mutation, are implicated in various cancers, including melanoma, colorectal cancer, and thyroid cancer.
